• LAST PRICE
    39.2950
  • TODAY'S CHANGE (%)
    Trending Down-0.5750 (-1.4422%)
  • Bid / Lots
    39.2800/ 1
  • Ask / Lots
    39.3100/ 6
  • Open / Previous Close
    39.3500 / 39.8700
  • Day Range
    Low 39.0100
    High 40.1290
  • 52 Week Range
    Low 11.3900
    High 40.1290
  • Volume
    773,162
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 39.87
TimeVolumeVRNA
09:32 ET3609439.44
09:33 ET2885339.2141
09:35 ET250039.72
09:37 ET1377539.72
09:39 ET117139.73
09:42 ET210039.915
09:44 ET435039.84
09:46 ET583839.65
09:48 ET265239.7135
09:50 ET268139.7044
09:51 ET553239.73
09:53 ET360839.5951
09:55 ET803639.435
09:57 ET536739.4
10:00 ET250039.615
10:02 ET479639.511
10:04 ET392839.6
10:06 ET2817739.5
10:08 ET1946439.28
10:09 ET130039.41
10:11 ET140039.38
10:13 ET133939.3057
10:15 ET143639.4016
10:18 ET90039.3175
10:20 ET494739.32
10:22 ET422139.2725
10:24 ET516839.305
10:26 ET115939.36
10:27 ET160039.345
10:29 ET394339.31
10:31 ET340039.35
10:33 ET80039.39
10:36 ET2122339.265
10:38 ET221339.3237
10:40 ET325939.385
10:42 ET840039.325
10:44 ET120139.315
10:45 ET1158839.395
10:47 ET1035439.305
10:49 ET3513439.06
10:51 ET120039.23
10:54 ET68139.275
10:56 ET627439.305
10:58 ET196939.4
11:00 ET1735839.38
11:02 ET314539.335
11:03 ET561939.27
11:05 ET746939.31
11:07 ET1027539.275
11:09 ET2817039.23
11:12 ET234639.42
11:14 ET817039.425
11:16 ET260739.28
11:18 ET30039.345
11:20 ET120039.25
11:21 ET123039.335
11:23 ET765839.2125
11:25 ET842039.175
11:27 ET420639.305
11:30 ET296939.15
11:32 ET90039.25
11:34 ET166439.25
11:36 ET20039.23
11:38 ET135039.28
11:39 ET70039.28
11:41 ET218839.33
11:43 ET80039.29
11:45 ET662839.25
11:48 ET51939.25
11:50 ET305839.18
11:52 ET120039.135
11:54 ET351639.155
11:56 ET473739.225
11:57 ET328039.275
11:59 ET2902739.2825
12:01 ET460039.46
12:03 ET358839.51
12:06 ET64239.47
12:08 ET60039.4621
12:10 ET138239.365
12:12 ET219439.37
12:14 ET110039.345
12:15 ET54239.334
12:17 ET40039.36
12:19 ET84139.325
12:21 ET201139.28
12:24 ET170039.315
12:26 ET40039.32
12:28 ET77639.35
12:30 ET260039.3835
12:32 ET233939.31
12:33 ET10039.31
12:35 ET29639.32
12:37 ET388339.39
12:39 ET22539.395
12:42 ET60039.375
12:44 ET60039.39
12:46 ET20039.39
12:48 ET10039.39
12:50 ET195239.39
12:51 ET315739.335
12:53 ET318539.335
12:55 ET211439.325
12:57 ET54339.315
01:00 ET185039.28
01:02 ET308739.295
01:04 ET292039.31
01:06 ET236939.355
01:08 ET100039.355
01:09 ET490339.28
01:11 ET242439.33
01:13 ET150439.295
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVRNA
Verona Pharma PLC
3.2B
-20.7x
---
United StatesIOVA
Iovance Biotherapeutics Inc
3.2B
-6.6x
---
United StatesEWTX
Edgewise Therapeutics Inc
3.3B
-23.4x
---
United StatesXENE
Xenon Pharmaceuticals Inc
3.3B
-15.9x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.1B
3,311.3x
---
United StatesMLTX
MoonLake Immunotherapeutics
3.4B
-40.5x
---
As of 2024-11-12

Company Information

Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.

Contact Information

Headquarters
Riverside, 3 More London PlaceLONDON, United Kingdom SE1 2RE
Phone
203-283-4200
Fax
207-863-3314

Executives

Non-Executive Independent Chairman of the Board
David Ebsworth
President, Chief Executive Officer, Executive Director
David Zaccardelli
Chief Financial Officer
Mark Hahn
General Counsel
Claire Poll
Chief Medical Officer
Kathleen Rickard

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.2B
Revenue (TTM)
$5.6M
Shares Outstanding
10.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.46
EPS
$-1.90
Book Value
$3.10
P/E Ratio
-20.7x
Price/Sales (TTM)
575.9
Price/Cash Flow (TTM)
---
Operating Margin
-2,827.79%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.